Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Many had misconceptions in a recent study.
Some who resolved hep B have seen their infection reactivate while on hep C therapy.
Despite the expansion of HIV treatment, rates of end-stage liver disease among those coinfected with hepatitis B or C remain unchanged.
Interim results of a mid-level trial suggest that six or eight weeks of odalasvir, AL-335 and Olysio (simeprevir) work well against hep C.
This disparity is driven by heavy drinking or injection drug use, an indication that changing such behaviors may save lives.
Even those who did not qualify for a treatment shorter than 12 weeks did well on the regimen in a real-world study.
Even light to moderate alcohol consumption is associated with developing liver cancer.
U.S. residents living with the virus frequently fail to undergo proper medical monitoring and treatment for the virus.
Well-controlled HIV was not associated with the march toward liver cirrhosis among those with hep C in a large trial.
The benefit is seen among with those with normal ALT levels, an indicator of liver health.
Researchers push the VA health care system to step up its game among baby boomer veterans.
The risk is highest for those with viral hepatitis and HIV.
Portal vein pressure is the cause of some of the most serious complications of liver cirrhosis.
Low levels of testing of children born to mothers with hep C are a troubling indicator.
The trend is occurring among women in Kentucky in particular.
Compared with restricting treatment to sicker individuals, treating all would also provide health and life span gains.